title: Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
authors.affiliation: Department of Oncology, Odense University Hospital, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Pfeiffer
authors.forename: C
authors.initials: C
authors.lastname: Rose
authors.forename: B
authors.initials: B
authors.lastname: Ejlertsen
authors.forename: M
authors.initials: M
authors.lastname: Andersson
authors.forename: D
authors.initials: D
authors.lastname: Pedersen
authors.forename: H T
authors.initials: HT
authors.lastname: Mouridsen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D009362:Neoplasm Metastasis; D013629:Tamoxifen / Q000008:administration & dosage
chemical_list: D013629:Tamoxifen; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil